Klinika KMK

Prenoto Vizitë

Abstract:

The emergence of COVID-19 has significantly transformed patient care paradigms, particularly in managing cardiovascular conditions such as non-valvular atrial fibrillation (NVAF). This article presents a thorough investigation conducted by the Association of Nutrition and Wellbeing, which aims to evaluate the personalized benefit-risk profiles of anticoagulants Warfarin and Rivaroxaban in post-COVID NVAF patients in Albania. By establishing a comprehensive database and deploying simulation models, this study seeks to provide crucial insights for optimizing anticoagulation therapy in this unique patient population.

Introduction:

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with increased risks of stroke and mortality. The management of NVAF, especially in patients with a history of COVID-19, introduces complex challenges for healthcare providers. COVID-19’s impact on the healthcare system has altered clinical protocols and patient management strategies. As anticoagulation remains a cornerstone of AF management, understanding the benefit-risk trade-offs between traditional therapies like Warfarin and newer agents such as Rivaroxaban is imperative. This investigation aims to personalize treatment approaches based on patient characteristics and clinical outcomes, thereby enhancing the quality of care for post-COVID patients.

Methods:

 The study was initiated with the formation of partnerships involving KMK Clinic as the primary data source, along with the Tirana Cardiology Center and the Association of General Practitioners. The methodology consists of the following phases:

  • Partnership Establishment: Formal agreements were established among the collaborating entities, clearly defining roles and responsibilities. This collaborative framework ensured a seamless execution of project activities.
  • Data Collection Protocol Development: In partnership with clinical experts and data analysts, a robust data extraction protocol was developed. This protocol is designed to standardize the collection of critical patient data, including demographic information, medical histories (specifically COVID-19 status and comorbidities), medication specifics (dosage and duration of Warfarin or Rivaroxaban), and relevant clinical outcomes such as incidence rates of stroke, bleeding events, and mortality.
  • Data Extraction Initiation: The retrospective data collection commenced at KMK Clinic, focusing on NVAF patients treated with either Warfarin or Rivaroxaban between January 2020 and September 2025. Access to patient records was prioritized to facilitate timely analysis.
  • Simulation Model Development: A preliminary simulation model was architected, incorporating vital patient characteristics (age, gender, comorbidities, and stroke history). Outcome probabilities were derived from an extensive review of existing literature and meta-analyses, aimed at estimating the individualized benefit-risk balance for the two anticoagulants.

Results:

Several significant outcomes have emerged during this reporting period:

  • Patient Database Development: A comprehensive database encompassing over 100 patients meeting the predefined study criteria was established. This database serves as a foundation for subsequent analyses and modeling efforts.
  • Preliminary Statistical Analysis: Initial statistical evaluations revealed notable trends indicating the efficacy and safety of Rivaroxaban compared to Warfarin, suggesting a potential shift in treatment paradigms for the post-COVID population.
  • Collaboration Enhancement: The partnering organizations have fostered a robust collaborative environment, facilitating effective communication and the exchange of best clinical practices among medical professionals.

Discussion:

The project has encountered several obstacles that impacted its implementation:

  • Data Access Delays: Initial delays in accessing comprehensive patient records were attributed to the ongoing disruptions caused by the COVID-19 pandemic. These challenges necessitated an extension of the data collection timeline, coupled with added support for clinic staff to expedite data extraction efforts.
  • Data Standardization Issues: Reconciling various data formats and clinical coding practices across collaborating institutions posed a significant challenge. To address this, rigorous enforcement of a standardized data extraction protocol was instituted, accompanied by training sessions for data analysts to ensure consistency in data entry and coding practices.
  • Clinician Engagement: Initial hesitance from some clinicians regarding the integration of structured, data-driven methodologies into routine patient management was noted. Overcoming this resistance involved ongoing dialogue, information sessions, and illustrating the potential benefits of data utilization in clinical decision-making.

The collaborative partnerships established have been pivotal in counteracting these adversities. The engagement with KMK Clinic has proven essential for securing access to patient records, while the involvement of the Tirana Cardiology Center and the Association of General Practitioners has provided essential expertise, facilitating the development of relevant clinical guidelines based on the findings. Their commitment to disseminating the preliminary results among their professional networks is expected to enhance clinical adoption and patient care practices.

Conclusion:

Preliminary analysis has highlighted the significant roles of age and comorbidities in shaping the benefit-risk profiles of Warfarin and Rivaroxaban.

Next Steps:

The project is progressing towards the final analysis report, alongside the development of a practical guideline for family physicians on the use of Warfarin and Rivaroxaban in this patient population.

Acknowledgments:

We extend our gratitude to all collaborating organizations and the healthcare professionals engaged in this study for their invaluable contributions.

Keywords:

Warfarin, Rivaroxaban, Non-Valvular Atrial Fibrillation, COVID-19, Personalized Medicine, Risk-Benefit Assessment, Albania